|
|
Post by mango on Jun 28, 2021 11:44:54 GMT -5
My understanding was those on medicare and insulin dependent could get a CGM covered but the insulin had to be an injectable. Now they can partner the CGM with afrezza and as VDex has demonstrated the CGM is a near requirement for learning initial dosing. I am sticking with my opinion this is huge news. Maybe I am wrong but I hope not. If we expect to become the Gold Standard for Time in Range we must marry Afrezza with the CGM. |
|
|
|
Post by nylefty on Jun 28, 2021 12:21:24 GMT -5
My understanding was those on medicare and insulin dependent could get a CGM covered but the insulin had to be an injectable. Now they can partner the CGM with afrezza and as VDex has demonstrated the CGM is a near requirement for learning initial dosing. I am sticking with my opinion this is huge news. Maybe I am wrong but I hope not. But somebody still has to pay for the Afrezza and almost all of the Medicare Part C and Part D plans have refused to do that. Medicare Part B, which is run by original Medicare. does cover CGMs. I realize that this is confusing since Medicare Parts A and B are run by original Medicare and Parts C and D are offered by private insurance plans. |
|
|
|
Post by mnkdfann on Jun 28, 2021 12:23:40 GMT -5
My understanding was those on medicare and insulin dependent could get a CGM covered but the insulin had to be an injectable. Now they can partner the CGM with afrezza and as VDex has demonstrated the CGM is a near requirement for learning initial dosing. I am sticking with my opinion this is huge news. Oh, is that the case? A 'near requirement'? I wasn't aware that VDex used CGMs so heavily. So, I wonder what percentage of VDex clients use CGMs? ( sportsrancho ? ) |
|
|
|
Post by factspls88 on Jun 28, 2021 12:28:31 GMT -5
|
|
|
|
Post by sportsrancho on Jun 28, 2021 12:28:42 GMT -5
My understanding was those on medicare and insulin dependent could get a CGM covered but the insulin had to be an injectable. Now they can partner the CGM with afrezza and as VDex has demonstrated the CGM is a near requirement for learning initial dosing. I am sticking with my opinion this is huge news. Oh, is that the case? A 'near requirement'? I wasn't aware that VDex used CGMs so heavily. So, I wonder what percentage of VDex clients use CGMs? ( sportsrancho ? ) All of them. Yes it’s essential, we get them on a CGM, teach them how to use that before we ever start them on Afrezza. We’ve also been billing Medicare for over a year. Mango has that snapshot that somebody wanted proof of on the first Vdex thread. I believe that was Casper. |
|
|
|
Post by mytakeonit on Jun 28, 2021 12:54:09 GMT -5
I am Wong, but never wrong. Did I hear someone say we are headed to $10  But, that's mytakeonit |
|
|
|
Post by sportsrancho on Jun 28, 2021 12:58:41 GMT -5
I am Wong, but never wrong. Did I hear someone say we are headed to $10 But, that's mytakeonit Absolutely, I just wanted to be happy and enjoy the stock going up but some people take all the joy out of it☹️ |
|
|
|
Post by goyocafe on Jun 28, 2021 13:08:04 GMT -5
My understanding was those on medicare and insulin dependent could get a CGM covered but the insulin had to be an injectable. Now they can partner the CGM with afrezza and as VDex has demonstrated the CGM is a near requirement for learning initial dosing. I am sticking with my opinion this is huge news. Maybe I am wrong but I hope not. If we expect to become the Gold Standard for Time in Range we must marry Afrezza with the CGM. SENS for T1s NMRD for T2s |
|
|
|
Post by sayhey24 on Jun 28, 2021 13:46:40 GMT -5
|
|
|
|
Post by goyocafe on Jun 28, 2021 14:36:33 GMT -5
I personally classify them as a CGM as a service company. Their strategy with their patch and monitoring service is to use a CGM patch for a shorter period of time, long enough to diagnose and prescribe, but not necessarily add CGM as a long term (think cost savings) part of the treatment plan. Fits right into VDEX’s use of a CGM to start users on Afrezza, but not necessarily to keep them on the CGM permanently. finance.yahoo.com/quote/NMRD/profile?p=NMRDNemaura Medical Inc., a medical technology company, discovers, develops, and commercializes diagnostic medical devices. The company provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as for screening pre-diabetic patients. It has a license agreement with Healthimation, LLC, which licenses the company to make, have made, use, offer to sell, sell, and import intensive medical diabetes and weight management program for Type 2 diabetes, prediabetes, and general wellness; the Why WAIT app; and common law trademarks which incorporate the mark WHY WAIT or WHYWAIT and the use of licensed marks. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York. |
|
|
|
Post by sayhey24 on Jun 28, 2021 14:53:51 GMT -5
Nemaura is a great example of the blending of the CGM market. It is not trying to be a medical device but rather a wellness device. It is in the same category as Sano and One Drop and Apple's "CGM" watch. IMO this is when "CGMs" become ubiquitous. Is sugarBeat good enough for afrezza dosing? It very well may be. Although the FDA will probably not allow them to say that. Apple is saying 2 years for their product.
I am loving "CGMs" becoming a commodity market. The more the better. Mike needs to be jumping all over these opportunities.
|
|
|
|
Post by morfu on Jun 28, 2021 16:02:26 GMT -5
Well, I just want to check if this is a good way to look at it:
The market has reacted to this news and the share price risen by about $1 so far and the company is thus about $250mil more valuable than on Thursday.
Assuming a P/E-ratio of 20 (or whatever) means, that this news can get generate additional revenue in the range of $250mil over that time frame.
(I am leaving it up to each of you to decide if that number is low or high, the company was valued fairly already and also if that news might affect the company in other ways than pure revenue like the increase stability of having one product in the Green potentially)
I am just wondering if this is a way to translate such news into share price expectations.
|
|
|
|
Post by cedafuntennis on Jun 28, 2021 16:06:15 GMT -5
PE of 20 is not for the kind of growth biotech market MNKD is part of. More like 50 - 75 I would say, but first we need to reach profitability for these multipliers to materialize.
|
|
|
|
Post by morfu on Jun 28, 2021 16:08:23 GMT -5
PE of 20 is not for the kind of growth biotech market MNKD is part of. More like 50 - 75 I would say, but first we need to reach profitability for these multipliers to materialize. I believe even you might manage to substitute a number... I tried to keep it simple. |
|
|
|
Post by itellthefuture777 on Jun 28, 2021 16:31:07 GMT -5
Tsunami=25,000,000 million patients now will have access to Afrezza...
Making friends of CGM makers..which can now..co-promote...hmm
|
|
